hydrogen carbonate has been researched along with Diabetes Mellitus, Type 2 in 41 studies
Bicarbonates: Inorganic salts that contain the -HCO3 radical. They are an important factor in determining the pH of the blood and the concentration of bicarbonate ions is regulated by the kidney. Levels in the blood are an index of the alkali reserve or buffering capacity.
hydrogencarbonate : The carbon oxoanion resulting from the removal of a proton from carbonic acid.
Diabetes Mellitus, Type 2: A subclass of DIABETES MELLITUS that is not INSULIN-responsive or dependent (NIDDM). It is characterized initially by INSULIN RESISTANCE and HYPERINSULINEMIA; and eventually by GLUCOSE INTOLERANCE; HYPERGLYCEMIA; and overt diabetes. Type II diabetes mellitus is no longer considered a disease exclusively found in adults. Patients seldom develop KETOSIS but often exhibit OBESITY.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Metformin-associated lactic acidosis (MALA) is a rare but life-threatening condition." | 8.12 | A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report. ( Ahmed, A; Gudowski, C; Mammadova, N; Pliquett, RU; Shkodivskyi, P; Soukup, J, 2022) |
| "Metformin-associated lactic acidosis (MALA) carries a high mortality rate." | 7.96 | Metformin-associated lactic acidosis: reinforcing learning points. ( Creagh, F; Goonoo, MS; Morris, R; Raithatha, A, 2020) |
| "Metformin-associated lactic acidosis is a severe and infrequent adverse event." | 7.85 | [Metformin-associated lactic acidosis. Report of one case]. ( Dreyse, J; Orozco, R; Pezzani, MJ; Quintana, F; Regueira, T; Soto, L, 2017) |
| " Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis." | 7.77 | Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases. ( Aytemiz, E; Begenik, H; Emre, H; Erkoc, R; Ozturk, M; Soyoral, YU, 2011) |
| "Metformin-associated lactic acidosis (MALA) is a rare but life-threatening condition." | 4.12 | A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report. ( Ahmed, A; Gudowski, C; Mammadova, N; Pliquett, RU; Shkodivskyi, P; Soukup, J, 2022) |
| "Metformin-associated lactic acidosis (MALA) carries a high mortality rate." | 3.96 | Metformin-associated lactic acidosis: reinforcing learning points. ( Creagh, F; Goonoo, MS; Morris, R; Raithatha, A, 2020) |
| "Metformin-associated lactic acidosis is a severe and infrequent adverse event." | 3.85 | [Metformin-associated lactic acidosis. Report of one case]. ( Dreyse, J; Orozco, R; Pezzani, MJ; Quintana, F; Regueira, T; Soto, L, 2017) |
| " Two cases of lactic acidosis due to ingestion of high dose metformin for suicidal purposes have been presented here; in both cases, clinical improvement was seen with bicarbonate hemodialysis." | 3.77 | Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases. ( Aytemiz, E; Begenik, H; Emre, H; Erkoc, R; Ozturk, M; Soyoral, YU, 2011) |
| "1478 FDS2 participants with type 2 diabetes (mean age 65." | 3.30 | Serum bicarbonate concentration and the risk of death in type 2 diabetes: the Fremantle Diabetes Study Phase II. ( Chubb, SAP; Davis, TME; Davis, WA, 2023) |
| "2,628 adults with type 2 diabetes and nephropathy." | 2.80 | Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St ( Bakker, SJ; de Zeeuw, D; Gansevoort, RT; Lambers Heerspink, HJ; Lewis, JB; Lutgers, HL; Schutte, E; Umanath, K; Vart, P; Wolffenbuttel, BH, 2015) |
| "Insulin resistance is closely associated with obesity and precedes the development of type 2 diabetes." | 2.53 | The role of dietary acid load and mild metabolic acidosis in insulin resistance in humans. ( Kozan, P; Samocha-Bonet, D; Williams, RS, 2016) |
| "We identified patients with type 2 diabetes, with ketone measurements available, who received SGLT2i (n = 82) or DPP4i (n = 308) during admission." | 1.91 | The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors. ( Bellomo, R; Ekinci, EI; Holmes, NE; Huang, W; Kishore, K; Marhoon, N; Neto, AS; Whitelaw, J, 2023) |
| "In a multivariable regression model, Type 2 diabetes was associated with over fourfold decreased odds of severe DKA (OR 0." | 1.91 | Clinical characteristics and severity of diabetic ketoacidosis: A cross-sectional study from a tertiary hospital in Ghana. ( Akpalu, J; Annan, OA; Aryee, R; Atiase, Y; Hayfron-Benjamin, C; Reynolds, M; Yawson, A; Yorke, E, 2023) |
| "Diabetic ketoacidosis is defined as hyperglycemia >250 mg/dL with metabolic acidosis of arterial pH <7." | 1.51 | Ketoacidosis in Euglycemic Patients With Type 2 Diabetes After Abdominal Surgery. ( Bennett, A; Geehan, D; Moncure, M; Segebrecht, R; Van Way, CW; Weide, L, 2019) |
| "Current criteria for the diagnosis of diabetic ketoacidosis (DKA) are limited by their nonspecificity (serum bicarbonate [HCO(3)] and pH) and qualitative nature (the presence of ketonemia/ketonuria)." | 1.35 | Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis? ( Basu, A; Karon, BS; Kudva, YC; Miles, JM; Muller, LA; Schwenk, WF; Sheikh-Ali, M; Xu, J, 2008) |
| "To describe features of pediatric-onset type 2 diabetes in the Hispanic population." | 1.30 | Early presentation of type 2 diabetes in Mexican-American youth. ( Chen, YD; Landon, C; Neufeld, ND; Raffel, LJ; Vadheim, CM, 1998) |
| "The diabetic coma is characterized by fundamental metabolic changes." | 1.27 | [Coma and praecoma diabeticum. Physiopathology, clinical aspects and therapy]. ( Sailer, D, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 4 (9.76) | 18.7374 |
| 1990's | 5 (12.20) | 18.2507 |
| 2000's | 8 (19.51) | 29.6817 |
| 2010's | 12 (29.27) | 24.3611 |
| 2020's | 12 (29.27) | 2.80 |
| Authors | Studies |
|---|---|
| Hansen, ESS | 1 |
| Bertelsen, LB | 1 |
| Bøgh, N | 1 |
| Miller, J | 1 |
| Wohlfart, P | 1 |
| Ringgaard, S | 1 |
| Laustsen, C | 1 |
| Mammadova, N | 1 |
| Soukup, J | 1 |
| Shkodivskyi, P | 1 |
| Gudowski, C | 1 |
| Ahmed, A | 1 |
| Pliquett, RU | 1 |
| Li, Y | 2 |
| Gao, R | 1 |
| Zhao, B | 1 |
| Zhang, Y | 1 |
| Mushailov, V | 1 |
| Horowitz, G | 1 |
| Dad, T | 1 |
| Liu, XY | 1 |
| Li, ZW | 1 |
| Zhang, B | 1 |
| Liu, F | 1 |
| Zhang, W | 1 |
| Peng, D | 1 |
| Fahy, Y | 1 |
| Laffey, JG | 1 |
| McNicholas, B | 1 |
| Huang, W | 1 |
| Whitelaw, J | 1 |
| Kishore, K | 1 |
| Neto, AS | 1 |
| Holmes, NE | 1 |
| Marhoon, N | 1 |
| Bellomo, R | 1 |
| Ekinci, EI | 1 |
| Chubb, SAP | 1 |
| Davis, WA | 2 |
| Davis, TME | 1 |
| Atiase, Y | 1 |
| Yorke, E | 1 |
| Akpalu, J | 1 |
| Reynolds, M | 1 |
| Annan, OA | 1 |
| Aryee, R | 1 |
| Hayfron-Benjamin, C | 1 |
| Yawson, A | 1 |
| Abu-Amer, N | 1 |
| Dinour, D | 1 |
| Mini, S | 1 |
| Beckerman, P | 1 |
| Geiger, H | 1 |
| Kaiser, M | 1 |
| Rudolf, S | 1 |
| Büttner, S | 1 |
| Goonoo, MS | 1 |
| Morris, R | 1 |
| Raithatha, A | 1 |
| Creagh, F | 1 |
| van Bommel, EJM | 1 |
| Geurts, F | 1 |
| Muskiet, MHA | 1 |
| Post, A | 1 |
| Bakker, SJL | 1 |
| Danser, AHJ | 1 |
| Touw, DJ | 1 |
| van Berkel, M | 1 |
| Kramer, MHH | 1 |
| Nieuwdorp, M | 1 |
| Ferrannini, E | 1 |
| Joles, JA | 1 |
| Hoorn, EJ | 1 |
| van Raalte, DH | 1 |
| Naumann, J | 1 |
| Biehler, D | 1 |
| Lüty, T | 1 |
| Sadaghiani, C | 1 |
| Quintana, F | 1 |
| Pezzani, MJ | 1 |
| Orozco, R | 1 |
| Dreyse, J | 1 |
| Soto, L | 1 |
| Regueira, T | 1 |
| Li, S | 1 |
| Wang, YY | 1 |
| Cui, J | 1 |
| Chen, DN | 1 |
| Xin, Z | 1 |
| Xie, RR | 1 |
| Cao, X | 1 |
| Lu, J | 1 |
| Yang, FY | 1 |
| Yang, JK | 1 |
| Segebrecht, R | 1 |
| Moncure, M | 1 |
| Bennett, A | 1 |
| Geehan, D | 1 |
| Van Way, CW | 1 |
| Weide, L | 1 |
| Tébar, MT | 1 |
| de Luis, N | 1 |
| Sánchez, I | 1 |
| Aguilera, L | 1 |
| Schutte, E | 1 |
| Lambers Heerspink, HJ | 1 |
| Lutgers, HL | 1 |
| Bakker, SJ | 1 |
| Vart, P | 1 |
| Wolffenbuttel, BH | 1 |
| Umanath, K | 1 |
| Lewis, JB | 1 |
| de Zeeuw, D | 1 |
| Gansevoort, RT | 1 |
| Williams, RS | 1 |
| Kozan, P | 1 |
| Samocha-Bonet, D | 1 |
| Paul Chubb, SA | 1 |
| Peters, KE | 1 |
| Davis, TM | 1 |
| Soyoral, YU | 1 |
| Begenik, H | 1 |
| Emre, H | 1 |
| Aytemiz, E | 1 |
| Ozturk, M | 1 |
| Erkoc, R | 1 |
| Costantino, M | 1 |
| Giampaolo, C | 1 |
| Filippelli, A | 1 |
| Mandel, EI | 1 |
| Curhan, GC | 1 |
| Hu, FB | 1 |
| Taylor, EN | 1 |
| Elinav, E | 1 |
| Ackerman, Z | 1 |
| Gottehrer, NP | 1 |
| Heyman, SN | 1 |
| Casteels, K | 1 |
| Mathieu, C | 1 |
| Prikis, M | 1 |
| Mesler, EL | 1 |
| Hood, VL | 1 |
| Weise, WJ | 1 |
| Sheikh-Ali, M | 1 |
| Karon, BS | 1 |
| Basu, A | 1 |
| Kudva, YC | 1 |
| Muller, LA | 1 |
| Xu, J | 1 |
| Schwenk, WF | 1 |
| Miles, JM | 1 |
| Lalau, JD | 1 |
| Debussche, X | 1 |
| Tolani, M | 1 |
| Arlot, S | 1 |
| Quichaud, J | 1 |
| Jarjis, HA | 1 |
| Blackburn, NA | 1 |
| Redfern, JS | 1 |
| Read, NW | 1 |
| Sailer, D | 1 |
| Block, MB | 1 |
| Mariano, F | 1 |
| Goia, F | 1 |
| Vincenti, R | 1 |
| Capra, L | 1 |
| Lanza, G | 1 |
| Curto, V | 1 |
| Cavalli, PL | 1 |
| Neufeld, ND | 1 |
| Raffel, LJ | 1 |
| Landon, C | 1 |
| Chen, YD | 1 |
| Vadheim, CM | 1 |
| Pushkin, A | 1 |
| Abuladze, N | 1 |
| Newman, D | 1 |
| Lee, I | 1 |
| Xu, G | 1 |
| Kurtz, I | 1 |
| Vantyghem, MC | 1 |
| Balduyck, M | 1 |
| Zerimech, F | 1 |
| Martin, A | 1 |
| Douillard, C | 1 |
| Bans, S | 1 |
| Degand, PM | 1 |
| Lefebvre, J | 1 |
| Urakami, T | 1 |
| Inami, I | 1 |
| Morimoto, S | 1 |
| Kubota, S | 1 |
| Owada, M | 1 |
| Woywodt, A | 1 |
| Kielstein, JT | 1 |
| Haller, H | 1 |
| Butler, PC | 1 |
| Kryshak, EJ | 1 |
| Marsh, M | 1 |
| Rizza, RA | 1 |
| Akanji, AO | 1 |
| Hockaday, TD | 1 |
| Hitanant, S | 1 |
| Vannasaeng, S | 1 |
| Tan-ngarm-trong, D | 1 |
| Plengvanit, U | 1 |
| Viranuvatti, V | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Study of Metformin Overdose in Adult Patients Treated at the University Hospital of Nancy: Single-center Descriptive Retrospective Observational Study[NCT04762966] | 50 participants (Anticipated) | Observational | 2021-03-01 | Recruiting | |||
| A Randomized, Double-blind, Comparator-controlled Trial to Assess the Effect of 12-week Treatment With Dapagliflozin Versus Gliclazide on Renal Physiology and Biomarkers in Metformin-treated Patients With Type 2 Diabetes Mellitus[NCT02682563] | Phase 4 | 44 participants (Actual) | Interventional | 2016-02-29 | Completed | ||
| Is There Any Effect of Maternal Dietary Acid Load During Pregnancy on Arising Gestational Diabetes Mellitus?[NCT03790579] | 80 participants (Actual) | Observational | 2014-01-05 | Completed | |||
| Alkaline Diet for Insulin Sensitivity[NCT02501343] | 32 participants (Actual) | Interventional | 2015-03-31 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Measured in kilograms (NCT02682563)
Timeframe: 12 weeks
| Intervention | kilograms (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 93.7 |
| Gliclazide Modified Release 30mg Once Daily | 99.6 |
Calculated from urinary and plasma para-aminohippurate concentrations, ERPF in ml/min (NCT02682563)
Timeframe: 12 weeks
| Intervention | ml/min (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 639 |
| Gliclazide Modified Release 30mg Once Daily | 678 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of glucose. Fractional excretion in % of filtered glucose (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered glucose (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 31.1 |
| Gliclazide Modified Release 30mg Once Daily | 0.6 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of potassium. Fractional excretion in % of filtered potassium (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered potassium (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 13.6 |
| Gliclazide Modified Release 30mg Once Daily | 11.8 |
Calculated fractional excretions with measured GFR (see above) and urinary and plasma concentrations of sodium. Fractional excretion in % of filtered sodium (NCT02682563)
Timeframe: 12 weeks
| Intervention | % of filtered sodium (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.74 |
| Gliclazide Modified Release 30mg Once Daily | 0.66 |
Calculated from urinary and plasma inulin concentrations, GFR in ml/min (NCT02682563)
Timeframe: 12 weeks
| Intervention | ml/min (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 104 |
| Gliclazide Modified Release 30mg Once Daily | 109 |
KIM-1 (ng/mmol) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
| Intervention | ng/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.25 |
| Gliclazide Modified Release 30mg Once Daily | 0.265 |
NGAL (ng/mmoll) measured in urine as a marker of renal damage (NCT02682563)
Timeframe: 12 weeks
| Intervention | ng/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 3.76 |
| Gliclazide Modified Release 30mg Once Daily | 3.79 |
Blood pressure will be measured using an automated oscillometric blood pressure device (Dinamap®) in mmHg (NCT02682563)
Timeframe: 12 weeks
| Intervention | mmHg (Mean) |
|---|---|
| Dapagliflozin 10mg Once Daily | 129.2 |
| Gliclazide Modified Release 30mg Once Daily | 131.1 |
Calculated from measured urinary albumin and creatinin concentrations, in mg/mmol (NCT02682563)
Timeframe: 12 weeks
| Intervention | mg/mmol (Median) |
|---|---|
| Dapagliflozin 10mg Once Daily | 0.88 |
| Gliclazide Modified Release 30mg Once Daily | 0.54 |
3 reviews available for hydrogen carbonate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Prevention and Therapy of Type 2 Diabetes-What Is the Potential of Daily Water Intake and Its Mineral Nutrients?
Topics: Adolescent; Adult; Aged; Animals; Bicarbonates; Biomarkers; Blood Glucose; Diabetes Mellitus, Type 2 | 2017 |
The role of dietary acid load and mild metabolic acidosis in insulin resistance in humans.
Topics: Acidosis; Bicarbonates; Diabetes Mellitus, Type 2; Diet; Female; Humans; Insulin Resistance; Male | 2016 |
Diabetic ketoacidosis.
Topics: Bicarbonates; Blood Chemical Analysis; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabeti | 2003 |
5 trials available for hydrogen carbonate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Serum bicarbonate concentration and the risk of death in type 2 diabetes: the Fremantle Diabetes Study Phase II.
Topics: Aged; Bicarbonates; Diabetes Mellitus, Type 2; Female; Humans; Longitudinal Studies; Male; Proportio | 2023 |
SGLT2 inhibition versus sulfonylurea treatment effects on electrolyte and acid-base balance: secondary analysis of a clinical trial reaching glycemic equipoise: Tubular effects of SGLT2 inhibition in Type 2 diabetes.
Topics: Acid-Base Equilibrium; Ammonium Compounds; Benzhydryl Compounds; Bicarbonates; Blood Glucose; Citrat | 2020 |
Serum Bicarbonate and Kidney Disease Progression and Cardiovascular Outcome in Patients With Diabetic Nephropathy: A Post Hoc Analysis of the RENAAL (Reduction of End Points in Non-Insulin-Dependent Diabetes With the Angiotensin II Antagonist Losartan) St
Topics: Adult; Aged; Angiotensin II Type 1 Receptor Blockers; Bicarbonates; Biphenyl Compounds; Diabetes Mel | 2015 |
Effect of insulin on oxidation of intracellularly and extracellularly derived glucose in patients with NIDDM. Evidence for primary defect in glucose transport and/or phosphorylation but not oxidation.
Topics: Adult; Bicarbonates; Biological Transport; Blood Glucose; Calorimetry; Carbon Dioxide; Diabetes Mell | 1990 |
Acetate tolerance and the kinetics of acetate utilization in diabetic and nondiabetic subjects.
Topics: Acetates; Adult; Bicarbonates; Diabetes Mellitus, Type 2; Dietary Fiber; Glucose; Glucose Tolerance | 1990 |
33 other studies available for hydrogen carbonate and Diabetes Mellitus, Type 2
| Article | Year |
|---|---|
Concentration-dependent effects of dichloroacetate in type 2 diabetic hearts assessed by hyperpolarized [1-
Topics: Acetates; Animals; Bicarbonates; Diabetes Mellitus, Type 2; Dichloroacetic Acid; Heart; Magnetic Res | 2022 |
A patient with severe metformin-associated lactic acidosis complicated by acute coronary syndrome: a case report.
Topics: Acidosis, Lactic; Acute Coronary Syndrome; Acute Kidney Injury; Bicarbonates; Diabetes Mellitus, Typ | 2022 |
Low Serum Bicarbonate Levels Increase the Risk of All-Cause, Cardiovascular Disease, and Cancer Mortality in Type 2 Diabetes.
Topics: Adult; Bicarbonates; Cardiovascular Diseases; Diabetes Mellitus, Type 2; Humans; Neoplasms; Nutritio | 2022 |
Low Serum Bicarbonate in a Patient With Diabetes Mellitus:: A Quiz.
Topics: Bicarbonates; Diabetes Mellitus; Diabetes Mellitus, Type 2; Humans; Risk Factors | 2023 |
Effects of preoperative bicarbonate and lactate levels on short-term outcomes and prognosis in elderly patients with colorectal cancer.
Topics: Aged; Bicarbonates; Colorectal Neoplasms; Diabetes Mellitus, Type 2; Disease-Free Survival; Humans; | 2023 |
Sodium-Glucose Cotransporter 2 Inhibitor-induced Ketoacidosis and Non-Ketotic Acidosis: When Is There a Role for Bicarbonate?
Topics: Acidosis; Bicarbonates; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Glucose; Humans; Ketosis; | 2023 |
The epidemiology of ketosis and low bicarbonate concentration in inpatients treated with sodium-glucose linked cotransporter inhibitors or dipeptidyl peptidase-4 inhibitors.
Topics: Bicarbonates; Cohort Studies; Diabetes Mellitus, Type 2; Dipeptidyl-Peptidase IV Inhibitors; Dipepti | 2023 |
Clinical characteristics and severity of diabetic ketoacidosis: A cross-sectional study from a tertiary hospital in Ghana.
Topics: Adult; Bicarbonates; Cross-Sectional Studies; Diabetes Mellitus, Type 2; Diabetic Ketoacidosis; Fema | 2023 |
An Unusual Case of Metabolic Acidosis: Clinical Case Education.
Topics: Acid-Base Equilibrium; Acidosis; Bicarbonates; Canagliflozin; Diabetes Mellitus, Type 2; Diabetic Ke | 2019 |
[Therapy of chronic metabolic acidosis among diabetologist].
Topics: Acidosis; Administration, Oral; Bicarbonates; Chronic Disease; Diabetes Mellitus, Type 1; Diabetes M | 2020 |
Metformin-associated lactic acidosis: reinforcing learning points.
Topics: Acidosis, Lactic; Acute Kidney Injury; Bicarbonates; Continuous Renal Replacement Therapy; Diabetes | 2020 |
[Metformin-associated lactic acidosis. Report of one case].
Topics: Acidosis, Lactic; Bicarbonates; Diabetes Mellitus, Type 2; Female; Hemofiltration; Humans; Hypoglyce | 2017 |
Are low levels of serum bicarbonate associated with risk of progressing to impaired fasting glucose/diabetes? A single-centre prospective cohort study in Beijing, China.
Topics: Adult; Bicarbonates; China; Diabetes Mellitus, Type 2; Disease Progression; Female; Glucose Toleranc | 2018 |
Ketoacidosis in Euglycemic Patients With Type 2 Diabetes After Abdominal Surgery.
Topics: 3-Hydroxybutyric Acid; Abdomen; Acidosis; Aged; Anions; Bicarbonates; Blood Glucose; Diabetes Mellit | 2019 |
[Metformin-associated lactic acidosis in the Intensive Care Unit].
Topics: Acidosis, Lactic; Aged; Aged, 80 and over; Bicarbonates; Combined Modality Therapy; Diabetes Mellitu | 2014 |
Serum bicarbonate concentration and the risk of cardiovascular disease and death in type 2 diabetes: the Fremantle Diabetes Study.
Topics: Aged; Bicarbonates; Biomarkers; Chi-Square Distribution; Coronary Disease; Diabetes Mellitus, Type 2 | 2016 |
Dialysis therapy for lactic acidosis caused by metformin intoxication: presentation of two cases.
Topics: Acidosis, Lactic; Adolescent; Bicarbonates; Diabetes Mellitus, Type 2; Dialysis Solutions; Humans; H | 2011 |
[Effects of drinking spa therapy on oxidative stress].
Topics: Administration, Oral; Aged; Bicarbonates; Blood Glucose; Calcium; Combined Modality Therapy; Diabete | 2012 |
Plasma bicarbonate and risk of type 2 diabetes mellitus.
Topics: Adult; Bicarbonates; Biomarkers; Case-Control Studies; Diabetes Mellitus, Type 2; Female; Humans; Lo | 2012 |
Recurrent life-threatening acidosis induced by acetazolamide in a patient with diabetic type IV renal tubular acidosis.
Topics: Acetazolamide; Acidosis; Aged; Aged, 80 and over; Bicarbonates; Carbonic Anhydrase Inhibitors; Diabe | 2002 |
When a friend can become an enemy! Recognition and management of metformin-associated lactic acidosis.
Topics: Acidosis, Lactic; Aged; Bicarbonates; Diabetes Mellitus, Type 2; Female; Humans; Hypoglycemic Agents | 2007 |
Can serum beta-hydroxybutyrate be used to diagnose diabetic ketoacidosis?
Topics: 3-Hydroxybutyric Acid; Adolescent; Adult; Bicarbonates; Biomarkers; Blood Glucose; Child; Diabetes M | 2008 |
[Lactic acidosis in diabetic patients treated with metformin. Value of hemodialysis with a sodium bicarbonate bath].
Topics: Acidosis; Aged; Bicarbonates; Diabetes Mellitus, Type 2; Humans; Lactates; Male; Metformin; Middle A | 1984 |
The effect of ispaghula (Fybogel and Metamucil) and guar gum on glucose tolerance in man.
Topics: Adult; Aged; Bicarbonates; Blood Glucose; Citrates; Citric Acid; Diabetes Mellitus, Type 2; Dietary | 1984 |
[Coma and praecoma diabeticum. Physiopathology, clinical aspects and therapy].
Topics: Bicarbonates; Diabetes Mellitus, Type 1; Diabetes Mellitus, Type 2; Diabetic Coma; Diabetic Ketoacid | 1984 |
Maximal dose glyburide therapy in markedly symptomatic patients with type II diabetes: a new use for an old friend.
Topics: Acid-Base Equilibrium; Bicarbonates; Diabetes Mellitus, Type 2; Glyburide; Humans; Hypoglycemic Agen | 1996 |
[Insufficient correction of blood bicarbonate levels in biguanide lactic acidosis treated with CVVH and bicarbonate replacement fluids].
Topics: Acidosis, Lactic; Acute Kidney Injury; Aged; Bicarbonates; Buffers; Diabetes Mellitus, Type 2; Drug | 1997 |
Early presentation of type 2 diabetes in Mexican-American youth.
Topics: Adolescent; Age Factors; Bicarbonates; Blood Glucose; Body Mass Index; C-Peptide; California; Child; | 1998 |
Cloning, characterization and chromosomal assignment of NBC4, a new member of the sodium bicarbonate cotransporter family.
Topics: Amino Acid Sequence; Bicarbonates; Binding Sites; Carrier Proteins; Chromosome Mapping; Cloning, Mol | 2000 |
Oxidative markers in diabetic ketoacidosis.
Topics: Adult; Antioxidants; Bicarbonates; Biomarkers; Blood Glucose; Blood Urea Nitrogen; Diabetes Mellitus | 2000 |
Clinical characteristics of non-immune-mediated, idiopathic type 1 (type 1B) diabetes mellitus in Japanese children and adolescents.
Topics: Adolescent; Age of Onset; Bicarbonates; Blood Glucose; C-Peptide; Child; Diabetes Mellitus, Type 1; | 2002 |
An uncommon cause of metabolic acidosis in a haemodialysis patient.
Topics: Acidosis; Adult; Bicarbonates; Diabetes Mellitus, Type 2; Diabetic Nephropathies; Dose-Response Rela | 2002 |
Exocrine pancreatic function among diabetic patients in Thailand.
Topics: Adolescent; Adult; Aged; Amylases; Bicarbonates; Cholecystokinin; Diabetes Mellitus, Type 1; Diabete | 1986 |